Replies to post #651491 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

Spelling mistakes and the use of the term 'comical'. This is definitely a post from fudster-extraordinaire. The fudster's post is devoid of any understanding of the positive developments in light of the successful trial. The fudster's post is of zero benefit to the investors, but is designed for the benefit of the fudster himself.

[Doc logic]

exwannabe,

Funny how a story about how to create a winner out of something initially tanking with then real skin in the game by that initial big investment, comparatively speaking to the period, gets turned into selfish Linda when all those precipitous years advanced into a pathway for all to benefit from while Linda eliminated her financial risk. I don’t see you complaining about those here playing with house money. Why not? Linda is playing with house money too and most current investors, if not all here, came in well after she made the initial big outlay where her risk was in play.

No one was forced to join in this venture and everyone in this sector has to know that development time is a big unknown that CEOs are legally allowed opportunity to underestimate, cover up with plausible deniability and obfuscate about with word salad forward looking statements. Lawyers are good at that and even been known to step on or strategically just over the line at times to keep their businesses or client businesses solvent. This is a surprise?; ).
In a perfect world all good health care ideas showing promise would get sufficient initial time period low rate federal financing continued when basic milestones are met, investors would not see their stock illegally manipulated by those seeking to benefit from an unfair advantage without good legal counter measures or tracking available and big pharma would offer a fair development offer early on based on product potential refined by product performance over time.

You can do better and longs know that right now is a great time to be invested or more invested. The science can be bad mouthed by those who have no credentials or those compromised with little to no effect on longs. Others can belittle this management team or make them out to just be self serving. That requires a totally blind eye be turned to the herculean effort that got this trial data and all other required scrit to inches from the finish line with the lean to the tape seemingly in slow motion after such a long wait. Will you really claim to be out this time like last time when this goes 10X plus from here/now this coming 365 as this ticker coils?; ).

This is going to be fun to watch. Approval, manufacturing, proteomics, tissue agnostic, combo trials and Direct all on the table at the same time as realistic nearer term than longer term. Global manufacturing scale up with potential partners CRL, MRK, BMY and others and reimbursement in the U.K. lining up with approval, all set to bring hope and promise for cancer patients into reality and you want me to look at two CDMOs that could get swallowed up in all the positioning? You gotta be kidding me!; ). Best wishes.

[biosectinvestor]

My comment about “allowing” votes was not my thought but a commentary on the previous posters contradictory comments and fickleness.

Obviously it’s a public company. And obviously as I said in a previous comment that despite her having “so few shares” as the previous poster had said, shareholders still voted for her and others to receive their compensation. The same goes for their shares.

As for funding CDMO’si have explained numerous times how that in fact reduces risk, and it’s a contract manufacturer. It was likely shorts that blew up the previous relationship and the long time for the trial that made selling the first CDMO, but they actually funded NWBO, and that arrangement was what blew up when shorts targeted it. Having first management buy out and then the sale to CRL was a positive development for the ecosystem, not some negative rip off. And you don’t know how much she put into that or puts into Advent even.

You’re supposed to make more than you put in and she saved the company and invested when it was necessary to keep a very long effort on track, something that does not always happen for companies like this. So quit the BS hammering of her.

I think you understate what she has put in and of course she is not going to put in the lions share of capital in a biotech as complex and long to validate as this one or any other. That’s just not how any of this works. As if Mark Zuckerberg or Elon Musk put in all the capital in all of their companies to own the equity they owned. Total nonsense.